Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability.

New arylthioindoles (ATIs) were obtained by replacing the 2-alkoxycarbonyl group with a bioisosteric 5-membered heterocycle nucleus. The new ATIs 5, 8, and 10 inhibited tubulin polymerization, reduced cell growth of a panel of human transformed cell lines, and showed higher metabolic stability than the reference ester 3. These compounds induced mitotic arrest and apoptosis at a similar level as combretastatin A-4 and vinblastine and triggered caspase-3 expression in a significant fraction of cells in both p53-proficient and p53-defective cell lines. Importantly, ATIs 5, 8, and 10 were more effective than vinorelbine, vinblastine, and paclitaxel as growth inhibitors of the P-glycoprotein-overexpressing cell line NCI/ADR-RES. Compound 5 was shown to have medium metabolic stability in both human and mouse liver microsomes, in contrast to the rapidly degraded reference ester 3, and a pharmacokinetic profile in the mouse characterized by a low systemic clearance and excellent oral bioavailability.

[1]  E. De Clercq,et al.  Synthesis and anti-VZV activity of 6-heteroaryl derivatives of tricyclic acyclovir and 9-{[cis-1',2'-bis(hydroxymethyl)cycloprop-1'-yl]methyl}guanine analogues. , 2009, European journal of medicinal chemistry.

[2]  Jian Ding,et al.  New microtubule-inhibiting anticancer agents , 2010, Expert opinion on investigational drugs.

[3]  E. Hamel,et al.  Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. , 1989, Biochemistry.

[4]  Ben Cornett,et al.  The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography , 2004, Science.

[5]  Stephen S. Taylor,et al.  Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. , 2008, Cancer cell.

[6]  Mathias Schmidt,et al.  Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  E. Nogales,et al.  High-Resolution Model of the Microtubule , 1999, Cell.

[8]  K. Gevaert,et al.  Mechanistic insight into taxol-induced cell death , 2008, Oncogene.

[9]  Andrea Brancale,et al.  Arylthioindoles, potent inhibitors of tubulin polymerization. , 2004, Journal of medicinal chemistry.

[10]  J. Bergman,et al.  Efficient synthesis of 2-chloro-, 2-bromo-, and 2-iodoindole , 1992 .

[11]  T. Fojo,et al.  The clinical development of new mitotic inhibitors that stabilize the microtubule. , 2004, Anti-cancer drugs.

[12]  G. Campiani,et al.  The Seco-Taxane IDN5390 Is Able to Target Class III β-Tubulin and to Overcome Paclitaxel Resistance , 2005 .

[13]  B. Bhattacharyya,et al.  anti-Mitotic Activity of Colchicine and the Structural Basis for Its Interaction with Tubulin , 2008 .

[14]  L. Galluzzi,et al.  Mitotic catastrophe: a mechanism for avoiding genomic instability , 2011, Nature Reviews Molecular Cell Biology.

[15]  Bruno Giethlen,et al.  Molecular Variations Based on Isosteric Replacements , 2008 .

[16]  Anna Ivana Scovassi,et al.  Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation, structure-activity relationships and molecular modeling studies. , 2007, Journal of medicinal chemistry.

[17]  P. Renard,et al.  Synthesis of isogranulatimide analogues possessing a pyrrole moiety instead of an imidazole heterocycle , 2003 .

[18]  W. Gerwick,et al.  Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. , 1998, Molecular pharmacology.

[19]  E. Hamel.  Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin , 2007, Cell Biochemistry and Biophysics.

[20]  G. Campiani,et al.  -Tubulin and to Overcome Paclitaxel Resistance β The Seco-Taxane IDN5390 Is Able to Target Class III , 2005 .

[21]  R. Hudkins,et al.  SYNTHESIS OF 2-ARYL- AND 2-VINYL-1H-INDOLES VIA PALLADIUM-CATALYZED CROSS-COUPLING OF ARYL AND VINYL HALIDES WITH 1-CARBOXY-2-(TRIBUTYLSTANNYL)INDOLE , 1995 .

[22]  M. Nardelli,et al.  Aggregative activation and heterocyclic chemistry I complex bases promoted arynic cyclisation of imines or enaminoketones; regiochemical synthesis of indoles , 1994 .

[23]  N. Nicola.  Granulocyte-colony stimulating factor , 1990, Immunology series.

[24]  T. Yen,et al.  Targeting Mitosis for Anti-Cancer Therapy , 2012, BioDrugs.

[25]  T. Mitchison,et al.  Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. , 2008, Cancer research.

[26]  M. Lautens,et al.  A highly selective tandem cross-coupling of gem-dihaloolefins for a modular, efficient synthesis of highly functionalized indoles. , 2008, The Journal of organic chemistry.

[27]  M. Gillett,et al.  Colchicine-induced bone marrow suppression: treatment with granulocyte colony-stimulating factor. , 2000, The Journal of emergency medicine.

[28]  Andrea Brancale,et al.  New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. , 2006, Journal of medicinal chemistry.

[29]  H. Tilson,et al.  Neurotoxic effects of colchicine. , 1990, Neurotoxicology.

[30]  Stephen S. Taylor,et al.  How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.

[31]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[32]  I. Barasoain,et al.  Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. , 2007, Nature chemical biology.

[33]  F. Mollinedo,et al.  Microtubules, microtubule-interfering agents and apoptosis , 2003, Apoptosis.

[34]  B. Teicher.  Newer Cytotoxic Agents: Attacking Cancer Broadly , 2008, Clinical Cancer Research.

[35]  E. Novellino,et al.  New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies. , 2009, Journal of medicinal chemistry.

[36]  Patrick A. Curmi,et al.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.

[37]  J. Bergman,et al.  Efficient Synthesis of 2-Chloro-, 2-Bromo-, and 2-Iodoindole. , 1992 .

[38]  E. Pasquier,et al.  Understanding microtubule dynamics for improved cancer therapy , 2005, Cellular and Molecular Life Sciences CMLS.

[39]  K. Bhalla.  Microtubule-targeted anticancer agents and apoptosis , 2003, Oncogene.

[40]  L. Di,et al.  Chapter 29 – Metabolic Stability Methods , 2008 .